Protocol Ledger

NCT04915729 · Phase III · COMPLETED

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Interventional Phase III clinical trial protocol NCT04915729 sponsored by Boehringer Ingelheim in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-22 Enrollment: 1,489 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04915729
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,489 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04915729
Protocol FieldVerified Registry Value
NCT IdentifierNCT04915729
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,489 participants (ACTUAL)
Registered Start Date2021-06-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04915729
Hospital Research SiteLocationSite Profile
Beijing Tsinghua Changgung HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
The Third Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI